Barclays Issues Pessimistic Forecast for Bausch Health Cos (NYSE:BHC) Stock Price

Bausch Health Cos (NYSE:BHC) had its price target lowered by stock analysts at Barclays from $8.00 to $7.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s target price would indicate a potential upside of 15.89% from the stock’s previous close.

A number of other brokerages also recently weighed in on BHC. Weiss Ratings downgraded shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research note on Thursday, February 19th. Wall Street Zen downgraded Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Truist Financial raised their price objective on Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a research report on Wednesday, January 7th. Finally, Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a report on Monday, January 26th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $8.33.

Bausch Health Cos Stock Performance

Shares of BHC stock opened at $6.04 on Wednesday. Bausch Health Cos has a 12 month low of $4.25 and a 12 month high of $8.69. The stock has a market cap of $2.24 billion, a PE ratio of 14.38 and a beta of 0.42. The company has a current ratio of 1.47, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68. The company’s fifty day moving average price is $6.55 and its 200-day moving average price is $6.69.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings results on Wednesday, February 18th. The company reported $1.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.21 by ($0.13). Bausch Health Cos had a return on equity of 875.00% and a net margin of 1.53%.The business had revenue of $2.78 billion during the quarter, compared to the consensus estimate of $2.71 billion. On average, equities analysts expect that Bausch Health Cos will post 4.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Bausch Health Cos

A number of hedge funds have recently added to or reduced their stakes in BHC. Paulson & CO. Inc. boosted its stake in Bausch Health Cos by 3.5% during the 4th quarter. Paulson & CO. Inc. now owns 73,255,869 shares of the company’s stock valued at $509,128,000 after purchasing an additional 2,500,000 shares during the last quarter. Goldentree Asset Management LP lifted its holdings in shares of Bausch Health Cos by 1.7% during the third quarter. Goldentree Asset Management LP now owns 34,833,431 shares of the company’s stock valued at $224,409,000 after purchasing an additional 578,542 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Bausch Health Cos by 4.0% during the third quarter. Vanguard Group Inc. now owns 12,241,072 shares of the company’s stock valued at $78,808,000 after purchasing an additional 470,968 shares in the last quarter. Maple Rock Capital Partners Inc. boosted its position in shares of Bausch Health Cos by 14.9% during the second quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company’s stock valued at $52,005,000 after buying an additional 1,010,987 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in Bausch Health Cos by 114.4% in the 2nd quarter. SG Americas Securities LLC now owns 6,152,986 shares of the company’s stock worth $40,979,000 after buying an additional 3,282,684 shares in the last quarter. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.